Alicia Castañeda Heredia
Investigador
Research group
Professional network profiles
Last Publications
- Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects Frontiers in oncology . 14: 1380917-1380917.
- Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy Cancers . 16(9): .
- Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes Cancers . 15(19): .
Projects
- Project name:
- Disrupción de enhancers: la nueva generación de terapia epigenética en el sarcoma de Ewing
- Leader
- Jaume Mora Graupera, Sara Sánchez Molina
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI24/00804
- Starting - finishing date:
- 2025 - 2027
- Project name:
- SEHOP-PENCIL study - Personalised mEdiciNe for Cancer in chILdren in Spain
- Leader
- Cinzia Emilia Lavarino
- Funding entities:
- Lavarino, Cinzia Emilia, Instituto de Salud Carlos III (ISCIII), Fundació Privada per a la Recerca i la Docència Sant Joan de Déu - FSJD
- Code
- PMP21/00075
- Starting - finishing date:
- 2022 - 2025
- Project name:
- GLEBioassay_Nano-Monitoring of Cancer Immunotherapy Efficiency: The Lateral Electrophoretic Bioassay platform.
- Leader
- Carlos Javier Rodriguez Hernandez
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- AC21_2/00045
- Starting - finishing date:
- 2022 - 2025
News
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.